UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August 26, 2025
Commission File Number: 0-29374
EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin - France
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F.
Form 20-F [ x] Form 40-F [ ]
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 26, 2025
EDAP TMS S.A.
/s/ KEN MOBECK
KEN MOBECK
CHIEF FINANCIAL OFFICER
EDAP Announces Letter of Intent for 36 Million
Euro Credit Facility to Accelerate Growth and Strategic Expansion
Funding to Support Continued Growth of Focal One® Robotic
HIFU
AUSTIN, Texas, August 26, 2025 - EDAP TMS SA
(Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced
execution of a letter of intent for EUR 36 million credit facility with the European Investment Bank (EIB). Proceeds from this financing
will support the continued expansion of Focal One® Robotic HIFU in Focal Therapy, the fastest-growing treatment category
for early-stage prostate cancer while accelerating the development of new clinical indications. Pending the signature of the final legal
documents, the Credit Facility is expected to close no later than the end of Calendar Year 2025.
“We are pleased to announce this
agreement on a letter of intent for such an important and strategic financing facility with the European Investment Bank,” said
Ryan Rhodes, Chief Executive Officer of EDAP. "The capital raised through this financing immediately enhances our balance sheet,
offering a substantial source of low-interest funding that we can access in tranches as needed." Over the last several years, the
EIB has been an extraordinary partner in helping companies deliver new and promising innovative technologies for the benefit of millions
of patients across the globe. I would like to thank the EIB for their support, as we believe this additional capital will enable more
physicians and their patients to access the benefits of Focal One Robotic HIFU.”
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP
TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using
ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP
introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy
controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company,
please visit https://focalone.com/.
Forward-Looking Statements
In addition to historical information, this press
release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S.
Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified
by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,”
“is designed to,” “may,” “might,” “potential,” “objective,” “target,”
“project,” “predict,” “forecast,” “ambition,” “guideline,” “should,”
“will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions,
which reflect our views about future events and financial performance. Such statements include our expectations to enter into a credit
facility with EIB, the size thereof, the timing thereof and the use of proceeds from such credit facility. Such statements are based on
management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not
currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will
actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking
statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for
our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain
worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic,
or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand
for our devices and services. Other factors that may cause such a difference may also include, but are not limited to, those described
in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on
Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the
date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future
developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of
this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited
or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
